Literature DB >> 10668633

Ischemia induced activation of heat shock protein 27 kinases and casein kinase 2 in the preconditioned rabbit heart.

S O Kim1, C P Baines, S D Critz, S L Pelech, S Katz, J M Downey, M V Cohen.   

Abstract

Protein kinase C (PKC), p38 MAP kinase, and mitogen-activated protein kinase-activated kinases 2 and 3 (MAPKAPK2 and MAPKAPK3) have been implicated in ischemic preconditioning (PC) of the heart to reduce damage following a myocardial infarct. This study examined whether extracellular signal-regulated kinase (Erk) 1, p70 ribosomal S6 kinase (p70 S6K), casein kinase 2 (CK2), and other hsp27 kinases are also activated by PC, and if they are required for protection in rabbit hearts. CK2 and hsp27 kinase activities declined during global ischemia in control hearts, whereas PC with 5 min ischemia and 10 min reperfusion increased their activities during global ischemia. Resource Q chromatography resolved two distinct peaks of hsp27 phosphotransferase activities; the first peak (at 0.36 M NaCl) appeared to correspond to the 55-kDa MAPKAPK2. Erk1 activity was elevated in both control and PC hearts after post-ischemic reperfusion, but no change was observed in p70 S6K activity. Infarct size (measured by triphenyltetrazolium staining) in isolated rabbit hearts subjected to 30 min regional ischemia and 2 h reperfusion was 31.0+/-2.6% of the risk zone in controls and was 10.3+/-2.2% in PC hearts (p<0.001). Neither the CK2 inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) nor the Mek1/2 inhibitor PD98059 infused during ischemia blocked protection by PC. The activation of CK2 and Erk1 in ischemic preconditioned hearts appear to be epiphenomena and not required for the reduction of infarction from myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10668633

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  11 in total

1.  Preconditioning for protection from ischemic injury: discriminating cause from effect from epiphenomenon.

Authors:  G B Bulkley
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

2.  H11 has dose-dependent and dual hypertrophic and proapoptotic functions in cardiac myocytes.

Authors:  Makoto Hase; Christophe Depre; Stephen F Vatner; Junichi Sadoshima
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

3.  Cardioprotection by mild hypothermia during ischemia involves preservation of ERK activity.

Authors:  Xiulan Yang; Yanping Liu; Xi-Ming Yang; Fangdi Hu; Lin Cui; Mark R Swingle; Richard E Honkanen; Peyman Soltani; Renaud Tissier; Michael V Cohen; James M Downey
Journal:  Basic Res Cardiol       Date:  2011-03-12       Impact factor: 17.165

4.  Secondary injury after musculoskeletal trauma: a review and update.

Authors:  Mark A Merrick
Journal:  J Athl Train       Date:  2002-04       Impact factor: 2.860

Review 5.  Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury.

Authors:  Elizabeth Murphy; Charles Steenbergen
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

Review 6.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

7.  Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation.

Authors:  Giuseppe Vassalli; Giuseppina Milano; Tiziano Moccetti
Journal:  J Transplant       Date:  2012-03-18

8.  CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways.

Authors:  Chinthasagar Bastian; John Quinn; Ajai Tripathi; Danielle Aquila; Andrew McCray; Ranjan Dutta; Selva Baltan; Sylvain Brunet
Journal:  Neurobiol Dis       Date:  2018-06-23       Impact factor: 7.046

9.  Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure.

Authors:  Matthew A Schechter; Michael K H Hsieh; Linda W Njoroge; J Will Thompson; Erik J Soderblom; Bryan J Feger; Constantine D Troupes; Kathleen A Hershberger; Olga R Ilkayeva; Whitney L Nagel; Gina P Landinez; Kishan M Shah; Virginia A Burns; Lucia Santacruz; Matthew D Hirschey; Matthew W Foster; Carmelo A Milano; M Arthur Moseley; Valentino Piacentino; Dawn E Bowles
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

Review 10.  Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning.

Authors:  A Lochner; E Marais; S Genade; B Huisamen; E F du Toit; J A Moolman
Journal:  Cardiovasc J Afr       Date:  2009 Jan-Feb       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.